
Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1 - 26. (Cancelled)

27. (Currently amended) A labeled nickel complex compound having formula I:



wherein:

B independently represents doubly bonded oxygen;

C represents carbon;

D independently represents nitrogen or oxygen;

L is a detectable label, optionally attached to a linker;


M represents a nickel ion;

b is from 0 to 6; n is 0 to 1; R' represents hydrogen, alkyl, aryl or a peptide chain;

R" is R, R' or G;

G represents OH, an amide or a DNA delivery agent; and

R represents a nitrogen-containing cationic group, optionally attached to a linker, wherein said cationic group is at least one C_b group linked to a nitrogen atom, $(CH_2)_3$ NH_2 , $(CH_2)_4$ NH_2 , C_bN $(C_b)_{0-3}$,



pyridyl .

- 28. (Previously presented) The labeled nickel complex compound of claim 27, wherein said DNA delivery agent comprises intercalators, oligonucleotides, proteins or polyamines.
- 29. (Currently amended) The labeled nickel complex compound of claim 27, wherein the label is a radioactive compound, a protein ligand, a fluorescent <u>compound</u> or an enzyme.
- 30. (Previously presented) The labeled nickel complex compound of claim 27, which is labeled with biotin.
- 31. (Previously presented) The labeled nickel complex compound of claim 27, wherein R' is a peptide chain.

32. (Currently amended) A labeled nickel complex compound, having formula A or

B:

wherein:


R' represents hydrogen, alkyl, aryl or a peptide chain;

R" represents R, R' or G;

L is a detectable label, optionally attached to a linker;

G represents -OH, -OR, an amide or a DNA delivery agent; and

R represents a nitrogen-containing cationic group optionally attached to a linker, wherein said cationic group is at least one C_b group linked to a nitrogen atom, $(CH_2)_3$ NH_2 , $(CH_2)_4$ NH_2 , C_bN $(C_6)_{0-3}$,



pyridyl ,

and wherein the label is a radioactive compound, a protein ligand, a fluorescent compound, or an enzyme, and the complex is labeled with biotin.

- 33. (Cancelled)
- 34. (Cancelled)
- 35. (Previously presented) A labeled nickel complex compound, which is Ni-salen-biotin complex.
- 36. (Currently amended) A labeled nickel complex compound, which is (Ni(salen-Lys(biotin) His Arg) complex.

Atty Dkt. No. 31182-6 Serial No. 10/019,655

- 37. (Previously presented) A method for detecting a non-canonical nucleic acid sequence comprising binding the labeled nickel complex compound of claim 27, to a sample of nucleic acid, and detecting a signal of the detectable label on the labeled nickel complex compound.
- 38. (Previously presented) The method of claim 37, wherein the detectable label is a radioactive compound, a protein ligand, a fluorescent compound, or an enzyme.
- 39. (Previously presented) The method of claim 37, wherein the detectable label is biotin.
- 40. (Previously presented) A method for detecting a non-canonical nucleic acid sequence comprising binding the labeled nickel complex compound of claim 32, to a sample of nucleic acid, and detecting a signal of the detectable label on the labeled nickel complex compound.
- 41. (Previously presented) The method of claim 40, wherein the detectable label is a radioactive compound, a protein ligand, a fluorescent compound, or an enzyme.
- 42. (Previously presented) The method of claim 40, wherein the detectable label is biotin.
- 43. (Previously presented) A labeled hybrid compound comprising the labeled nickel complex compound of claim 27, complexed with a protein or oligonucleotide.
- 44. (Previously presented) The labeled hybrid compound of claim 43, wherein the labeled nickel complex compound is labeled with a radioactive compound, a protein ligand, a fluorescent compound or an enzyme.

Atty Dkt. No. 31182-6 Serial No. 10/019,655

45. (Cancelled)

- 46. (Previously presented) The labeled hybrid compound of claim 43, which is labeled with biotin.
- 47. (Previously presented) The labeled hybrid compound of claim 43, which is labeled with a green fluorescent protein or epitope.
- 48. (Previously presented) A labeled hybrid compound comprising the labeled nickel complex compound of claim 32, complexed with a protein or oligonucleotide.
- 49. (Previously presented) The labeled hybrid compound of claim 48, wherein the labeled nickel complex compound is labeled with a radioactive compound, a protein ligand, a fluorescent compound or an enzyme.
- 50. (Currently amended) The labeled hybrid compound of claim 49, which is complexed with the protein; wherein a penultimate amino acid from the N-terminus of the protein is histidine.
- 51. (Previously presented) The labeled hybrid compound of claim 48, which is labeled with biotin.
- 52. (Previously presented) The labeled hybrid compound of claim 48, which is labeled with a green fluorescent protein or epitope.
- 53. (Previously presented) A method for detecting or measuring protein-nucleic acid interaction comprising mixing the labeled hybrid compound of claim 43, with a solution of nucleic acid, and assaying for the signal from a detectable label attached to the nucleic acid.

Atty Dkt. No. 31182-6 Serial No. 10/019,655

- 54. (Previously presented) The method of claim 53, wherein said label is a radioactive compound, a protein ligand, a fluorescent compound, or an enzyme.
- 55. (Previously presented) A method for purifying a nucleic acid-nickel-complex adduct, comprising:
- a) mixing the labeled nickel complex compound of claim 27, with a solution of DNA,
- b) subjecting the mixture of step a) to a separation medium, wherein the medium contains a material that specifically binds to the label, and
- c) separating the bound medium from the solution mixture, wherein the adduct is bound to the material of the separation medium.
- 56. (Previously presented) The method of claim 55, wherein said separation medium is affinity chromatogram.
- 57. (Previously presented) The method of claim 56, wherein said label is biotin, and the material in the separation medium binds to biotin.
- 58. (Previously presented) The method of claim 57, wherein the material binding to biotin is avidin.
- 59. (Previously presented) The method of claim 57, wherein the material binding to biotin is streptavidin.
- 60. (Previously presented) A method for purifying a nucleic acid-nickel-complex adduct, comprising:
- a) mixing the labeled nickel complex compound of claim 32, with a solution of DNA,
- b) subjecting the mixture to a separation medium, wherein the medium contains a material that specifically binds to the label, and

- c) separating the bound medium from the solution mixture, wherein the adduct is bound to the material of the separation medium.
- 61. (Previously presented) The method of claim 60, wherein said separation medium is affinity chromatogram.
- 62. (Previously presented) The method of claim 61, wherein the label is biotin, and the material in the separation medium binds to biotin.
- 63. (Previously presented) The method of claim 62, wherein the material binding to biotin is avidin.
- 64. (Previously presented) The method of claim 62, wherein the material binding to biotin is streptavidin.
- 65. (Previously presented) A method for detecting or measuring protein-nucleic acid interaction comprising mixing the labeled hybrid compound of claim 43, with a solution of nucleic acid, and assaying for the signal from a detectable label attached to the nucleic acid.
- 66. (Previously presented) The method of claim 53, wherein said label is a radioactive compound, a protein ligand, a fluorescent compound, or an enzyme.